Stock Analysis

MiNK Therapeutics Executive Chairman Acquires 5.3% More Stock \

NasdaqCM:INKT
Source: Shutterstock

Even if it's not a huge purchase, we think it was good to see that Garo Armen, the Executive Chairman of MiNK Therapeutics, Inc. (NASDAQ:INKT) recently shelled out US$95k to buy stock, at US$0.95 per share. However, it only increased their shares held by 5.3%, and it wasn't a huge purchase by absolute value, either.

View our latest analysis for MiNK Therapeutics

MiNK Therapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by Garo Armen is the biggest insider purchase of MiNK Therapeutics shares that we've seen in the last year. We do like to see buying, but this purchase was made at well below the current price of US$1.58. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

While MiNK Therapeutics insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqCM:INKT Insider Trading Volume May 6th 2023

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Does MiNK Therapeutics Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that MiNK Therapeutics insiders own 8.9% of the company, worth about US$4.7m. We do generally prefer see higher levels of insider ownership.

So What Do The MiNK Therapeutics Insider Transactions Indicate?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that MiNK Therapeutics insiders are expecting a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 6 warning signs for MiNK Therapeutics (4 are potentially serious!) and we strongly recommend you look at these before investing.

Of course MiNK Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqCM:INKT

MiNK Therapeutics

A clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

Medium-low with weak fundamentals.